vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Primis Financial Corp. (FRST). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $45.6M, roughly 1.4× Primis Financial Corp.). Primis Financial Corp. runs the higher net margin — 16.0% vs -70.9%, a 87.0% gap on every dollar of revenue. Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 13.0%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
CTKB vs FRST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $45.6M |
| Net Profit | $-44.1M | $7.3M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | — |
| Net Margin | -70.9% | 16.0% |
| Revenue YoY | 8.1% | — |
| Net Profit YoY | -557.1% | 200.0% |
| EPS (diluted) | — | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $45.6M | ||
| Q4 25 | $62.1M | $80.9M | ||
| Q3 25 | $52.3M | $41.0M | ||
| Q2 25 | $45.6M | $43.2M | ||
| Q1 25 | $41.5M | $58.7M | ||
| Q4 24 | $57.5M | $38.8M | ||
| Q3 24 | $51.5M | $37.3M | ||
| Q2 24 | $46.6M | $35.7M |
| Q1 26 | — | $7.3M | ||
| Q4 25 | $-44.1M | $29.5M | ||
| Q3 25 | $-5.5M | $6.8M | ||
| Q2 25 | $-5.6M | $2.4M | ||
| Q1 25 | $-11.4M | $22.6M | ||
| Q4 24 | $9.6M | $-26.2M | ||
| Q3 24 | $941.0K | $1.2M | ||
| Q2 24 | $-10.4M | $3.4M |
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.0% | 44.8% | ||
| Q3 25 | -17.6% | 21.3% | ||
| Q2 25 | -23.3% | 6.9% | ||
| Q1 25 | -36.1% | 41.9% | ||
| Q4 24 | 5.2% | -123.0% | ||
| Q3 24 | -8.2% | -3.1% | ||
| Q2 24 | -18.3% | 7.8% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | -70.9% | 36.5% | ||
| Q3 25 | -10.5% | 16.7% | ||
| Q2 25 | -12.2% | 5.6% | ||
| Q1 25 | -27.5% | 38.6% | ||
| Q4 24 | 16.8% | -100.3% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | -22.4% | 9.6% |
| Q1 26 | — | $0.30 | ||
| Q4 25 | — | $1.19 | ||
| Q3 25 | — | $0.28 | ||
| Q2 25 | — | $0.10 | ||
| Q1 25 | — | $0.92 | ||
| Q4 24 | — | $-0.95 | ||
| Q3 24 | — | $0.05 | ||
| Q2 24 | — | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $159.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $427.2M |
| Total Assets | $461.5M | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $159.9M | ||
| Q4 25 | $90.9M | $143.6M | ||
| Q3 25 | $93.3M | $63.9M | ||
| Q2 25 | $75.5M | $94.1M | ||
| Q1 25 | $95.3M | $57.0M | ||
| Q4 24 | $98.7M | $64.5M | ||
| Q3 24 | $162.3M | $77.3M | ||
| Q2 24 | $177.9M | $66.6M |
| Q1 26 | — | $427.2M | ||
| Q4 25 | $341.7M | $422.9M | ||
| Q3 25 | $378.6M | $382.2M | ||
| Q2 25 | $377.6M | $376.4M | ||
| Q1 25 | $379.6M | $375.6M | ||
| Q4 24 | $395.7M | $351.8M | ||
| Q3 24 | $385.5M | $381.0M | ||
| Q2 24 | $389.1M | $376.0M |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $461.5M | $4.0B | ||
| Q3 25 | $494.9M | $4.0B | ||
| Q2 25 | $493.3M | $3.9B | ||
| Q1 25 | $482.6M | $3.7B | ||
| Q4 24 | $499.5M | $3.7B | ||
| Q3 24 | $491.2M | $4.0B | ||
| Q2 24 | $483.7M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | — |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-771.0K | $10.8M | ||
| Q3 25 | $-3.9M | $-11.4M | ||
| Q2 25 | $108.0K | $-41.0M | ||
| Q1 25 | $-125.0K | $34.4M | ||
| Q4 24 | $2.0M | $19.5M | ||
| Q3 24 | $13.2M | $6.1M | ||
| Q2 24 | $6.2M | $52.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $9.0M | ||
| Q3 25 | $-4.6M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-974.0K | — | ||
| Q4 24 | $1.1M | $18.3M | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $5.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | 11.2% | ||
| Q3 25 | -8.7% | — | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -2.3% | — | ||
| Q4 24 | 1.9% | 47.3% | ||
| Q3 24 | 23.7% | — | ||
| Q2 24 | 11.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 2.1% | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.6% | 3.1% | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 2.3% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.36× | ||
| Q3 25 | — | -1.67× | ||
| Q2 25 | — | -16.82× | ||
| Q1 25 | — | 1.52× | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 4.93× | ||
| Q2 24 | — | 15.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
